ERBB2 and breast carcinoma: Moreover, simultaneous targeting of αVβ6 and HER2 effectively eliminates tumors in mouse xenograft models of trastuzumab-sensitive breast cancer, suggesting that cotargeting αVβ6 and HER2 represents a potential therapeutic avenue for treating breast cancer (17).